Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland by French, K M et al.
Strategies for the introduction of human papillomavirus
vaccination: modelling the optimum age- and sex-specific
pattern of vaccination in Finland
KM French*,1, RV Barnabas
1,2, M Lehtinen
3, O Kontula
4, E Pukkala
5, J Dillner
6 and GP Garnett
1
1Department of Infectious Disease Epidemiology, Imperial College, Norfolk Place, Paddington, London, W2 1PG, UK;
2HIV Vaccine Trials Network, Seattle,
USA;
3National Public Health Institute, Finland;
4Family Federation of Finland, Finland;
5Finnish Cancer Registry, Institute for Statistical and Epidemiological
Cancer Research, Finland;
6Lund University, Sweden
Phase III trials have demonstrated the efficacy of human papillomavirus (HPV) vaccines in preventing transient and persistent high-risk
(hr) HPV infection and precancerous lesions. A mathematical model of HPV type 16 infection and progression to cervical cancer,
parameterised to represent the infection in Finland, was used to explore the optimal age at vaccination and pattern of vaccine
introduction. In the long term, the annual proportion of cervical cancer cases prevented is much higher when early adolescents
are targeted. Vaccinating against hr HPV generates greater long-term benefits if vaccine is delivered before the age at first sexual
intercourse. However, vaccinating 12 year olds delays the predicted decrease in cervical cancer, compared to vaccinating older
adolescents or young adults. Vaccinating males as well as females has more impact on the proportion of cases prevented when
vaccinating at younger ages. Implementing catch-up vaccination at the start of a vaccination programme would increase the speed
with which a decrease in HPV and cervical cancer incidence is observed.
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Human papillomavirus (HPV) is a common sexually transmitted
agent (Trottier and Franco, 2006) and persistent infection with
high risk (hr) types of HPV, most notably types 16 and 18, is the
most important risk factor for cervical cancer (Ho et al, 1998).
Rates of invasive cervical cancer (ICC) in fertile aged women in
Finland declined significantly from 1960 to 1990 (Figure 1), mostly
as a result of the national screening programme. However, cervical
cancer incidence in Finnish women aged 30–39 years is now
four times higher than 15 years ago (2.9/100000 in 1986–1990; 9.8/
100000 in 2000–2004: Finnish Cancer Registry, 2006). This is
probably due to an increase in incidence and prevalence of hr HPV
types in young (23–28 year old) Finnish women (Laukkanen et al,
2003; Lehtinen et al, 2006).
In phase III trials, two HPV virus-like particle vaccines have
been shown effective in preventing incident and persistent HPV16
and 18 infection and associated precancerous lesions, with
reported efficacies in the region of 90–100% (Koutsky et al,
2002; Harper et al, 2004, 2006; Villa et al, 2005; Mao et al, 2006).
The vaccines could prevent around 70% of all cervical cancer
(Munoz et al, 2003). One vaccine has recently been licensed for use
in the US and in Europe. However, there remain important
questions about how a HPV vaccine should be used at a population
level (Lowndes and Gill, 2005). These include: the age chosen for
vaccination, whether the vaccine is given to female subjects only or
to female and male subjects and whether a catch-up vaccination
campaign should accompany the introduction of routine vaccina-
tion. As mathematical models provide a framework for exploring
these questions (Garnett, 2002), we have examined these questions
with a model of single-type HPV using the observed epidemiology
of HPV in Finland (Barnabas et al, 2006).
MATERIALS AND METHODS
In earlier work, we used sexual behaviour data along with HPV
seroprevalence trends in pregnant women to parameterise a
mathematical model of HPV16 occurrence in Finland (Barnabas
et al, 2006). This provided a framework which we developed
further to explore the impact of age at first sexual intercourse, and
the age of vaccination on occurrence of HPV16 and associated
cervical cancer cases. The model stratified the population by 5-year
age groups. To explore aspects of age of vaccination, we adapted
the model to represent single years of age, with a gradual increase
in the proportion of adolescents who were sexually active. The
earlier detailed description of the model is still applicable and is
summarised here. The population was stratified into age, sex and
sexual activity classes with defined rates of sexual partner change
(Barnabas et al, 2006). The model describes the transmission of
virus between the sexes and the flow of incident cases in women
from the acquisition of asymptomatic HPV infection, through
premalignant disease to ICC, with most HPV infections regressing
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clearance of infection results in lifelong acquired immunity. The
rates of regression and progression between stages of disease used
in the earlier model (Barnabas et al, 2006) were adapted to allow
linear increase and decrease in rates with age rather than a sudden
increase in progression rates at age 35. Cervical screening was based
on the reported age-specific proportion of women screened through
the national Finnish screening programme as in the earlier model
(Barnabas et al, 2006). Screening starts at the age of 25 or 30 years
(in the model at age 25) and continues up to age 60 with a screening
interval of 5 years. Successful identification of HPV infection and
associated precancerous lesions and its treatment was assumed to
result in lifelong acquired immunity. It was assumed that screening
did not change after the introduction of vaccination. A simple
representation of infection in men was used, assuming they could be
susceptible, infected or immune.
The proportion of the population sexually active at each age was
set according to data from the Family Federation of Finland,
with the percentages sexually active by age shown in Table 1.
Although data on the age of sexual debut from 12 years and
older were available, partner change rates were not available for
12–14-years-old and we assumed that for this age group partner
change rates were similar to that at age 15–19 years.
We explored the impact of vaccination on cases of cervical
cancer. For different ages at vaccine delivery (12, 15, 18 and 21), we
compared the predicted proportion of cervical cancer caused by
HPV16 prevented by vaccination of 70% of female subjects
introduced in 2008. For simplicity, we assumed that the vaccine
has 100% efficacy with lifelong duration of protection and that the
vaccine had no effect on those already infected. The additional
proportion of cervical cancer cases prevented by vaccinating male
as well as female subjects at different coverages, and by different
strategies of catch-up vaccination at the start of a campaign was
also examined. We assumed 3 years of catch-up vaccination at the
start of a vaccination campaign aimed at 12-years-old, corresponds
to vaccinating at ages 12, 13, 14 and 15 in the first year of the
campaign. We explored four catch-up vaccination strategies
corresponding to 3, 6, 9 and 12 additional years age cohorts
vaccinated in the first year.
RESULTS
The model predicts that vaccinating young adolescents at 12 years
of age, compared with 15-years-old, delays the impact of
immunisation on HPV16-associated cervical cancer incidence
(Figure 2A). Before age 16, only a small proportion of the
population is sexually active and transmitting the infection
(Table 1); it is as the vaccinated cohort ages and becomes sexually
active that an impact on incidence is observed. Infection before
vaccination results in the impact of vaccination declining as
the age of vaccination increases when more of the population is
sexually active and HPV incidence is higher. The predicted peak
HPV incidence in women (and in men), generating the observed
pattern of disease before vaccination, is seen at age 20. Once
the full impact of vaccination is reached, the annual proportion of
cases of HPV16-associated cervical cancer prevented is 20% if
vaccination occurs at age 21; 40% if this occurs at age 18; 67% if it
occurs at age 15; and 68% if it occurs at age 12. There is relatively
little difference, especially in the long term between vaccinating at
12 and 15 years of age (Figure 2A).
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Figure 1 Cervical cancer incidence per 100000 women per year in
Finland by age at diagnosis. Data from the Finnish Cancer Registry.
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Figure 2 Proportion of annual incident HPV16-associated cervical
cancer cases prevented with different ages at vaccination if coverage is
70% of females only (A). Additional proportion of total HPV16-associated
cervical cancer cases prevented for each age at vaccination by vaccinating
male as well as female subjects with the same 70% coverage (B) and catch-
up vaccination that involves vaccinating three additional ages in the first year
of vaccination with the same 70% coverage (C).
Table 1 Percentage of each age that is sexually active in the model
Age 12 13 14 15 16 17 18 19 20+
Sexually active (%) 0.6 1.7 4.4 10.6 30.0 50.0 65.0 80.0 99–100
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to female subjects depends upon the age of vaccination and the
coverage. At younger ages, the number of additional cases
prevented is greater (Figure 2B). In the long-term, vaccinating
male as well as female subjects at ages 12 or 15 annually prevents
an additional 15.1 and 15.5% of cases, respectively. If vaccination
occurs at age 21, vaccinating male subjects has very little effect on
incidence of cervical cancer, in the long-term preventing annually
an additional 1% of cases. The benefit of vaccinating both sexes, in
terms of the proportion of cervical cancer cases prevented,
increases with vaccination coverage, peaking at 50% coverage
(Table 2). If vaccination occurs at age 12, vaccinating male as well
as female subjects at 30 or 70% coverage prevents an additional
15% of cases, whereas at 50% coverage an additional 18% of cases
are prevented annually.
Three years of catch-up vaccination at the start of a campaign
also has more impact at younger ages of vaccination (Figure 2C)
because the ages included in the catch-up occur before the age of
peak incidence. In the first 10 years after the start of the
vaccination campaign, 3 years of catch-up prevents an additional
6% of cervical cancer cases if vaccination occurs at age 21, 10% if
this occurs at age 18, 18% if it occurs at age 15 and 15% if it occurs
at age 12.
Although the relative impact of 3-year catch-up vaccination
on the proportion of cases prevented annually in the long term is
highest if vaccination occurs at age 12 (Figure 2A and C), the
absolute cumulative number of cases of HPV16-associated cervical
cancer prevented by 2055 both with and without the 3-year
catch-up is highest if vaccination occurs at age 15 (Table 3). In the
former, the impact of vaccination takes 3 years longer to be
realised as only a small proportion of the population is sexually
active before age 15. In contrast, when vaccinating at ages 18 or 21,
because a large proportion of infections occur before vaccination,
the number of cumulative cases prevented is lower.
Increasing the range of ages included in a catch-up vaccina-
tion programme aimed at 12-years-old beyond 6 years, yields
diminishing returns (Figure 3). A 6-year catch-up programme,
vaccinating ages 12–18 inclusive, prevents an additional 11% of
HPV16-associated cervical cancer cases in the first 10 years
compared with a 3-year catch-up programme, vaccinating ages
12–15 inclusive. A further 3 years, vaccinating ages 12–21,
prevents an additional 5% and another 3 years, vaccinating ages
12–24, prevents an additional 3% of cases in the first 10 years.
Figure 4 shows the impact of selected possible vaccination
strategies on HPV16-associated cervical cancer cases. With a
vaccination programme aimed at 15-year-old female subjects, a
predicted 71% cases of HPV16-associated cervical cancer could be
prevented annually by 2055, when the full impact of the campaign
is realised (Figure 4). If a 3-year catch-up vaccination is included
(so the first year of the programme involves vaccinating 15–18-
year-old female subjects), the proportion of cases prevented in the
long term is not changed, but the impact is observed sooner
(Figure 4). If the age at vaccinating females is lowered to age 12
and 6 years of catch-up vaccination is included, 75% of cases could
be prevented each year by 2055 (Figure 4). If vaccination is aimed
at 15-year-old male and female subjects, with a 3-year catch-up
vaccination in females only, a predicted 86% of HPV16-associated
cervical cancer cases could be prevented annually by 2055
(Figure 4). If, alternatively, vaccination is aimed at 12-year-old
males and females, with or without catch-up vaccination, the
annual proportion of cases prevented by 2055 is 90%, though
without catch-up the impact takes longer to be realised (Figure 4).
DISCUSSION
Modelling the dynamics of HPV infection and impact of
vaccination based on empirical data (Koutsky et al, 2002; Harper
et al, 2004; Villa et al, 2005; Barnabas et al, 2006; Harper et al,
2006) allows us to predict the patterns of infection and disease
associated with a range of strategies. Qualitative rules emerge: (1)
vaccinating before sexual debut maximises the long-term impact of
vaccination; (2) catch-up programmes can speed impact and
Table 2 Additional annual percentage of cervical cancer cases prevented
by vaccinating male subjects in addition to female subjects by vaccination
coverage and age
Age at vaccination
Vaccination coverage (%) 12 15 18 21
10 6.1 5.6 1.7 0.2
30 14.8 13.9 4.3 0.4
50 18.1 17.4 6.0 0.6
70 15.1 15.5 6.6 0.7
90 5.8 7.9 6.0 0.7
Table 3 Cumulative HPV16-associated cervical cancer cases prevented by year 2055 vaccinating female subjects only with 70% coverage with and
without 3-year catch-up vaccination
Age at
vaccination
Cumulative cases prevented
by 2055 no catch-up
Cumulative cases prevented
by 2055 with 3-year catch-up
Additional cases prevented by
3-year catch-up
Percentage
increase (%)
12 1217.8 1382.4 164.6 13.5
15 1295.5 1408.3 112.8 8.7
18 776.2 830.9 54.7 7.1
21 385.9 422.8 36.9 9.6
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Figure 3 Additional proportion of total HPV16-associated cervical
cancer cases prevented by vaccination with different numbers of ages
included in a catch-up programme. Vaccination is at age 12 with 70%
coverage of female subjects only and catch-up applied in the first year.
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subjects prevents additional cases, but the proportion is smaller
than the concomitant increase in the fraction vaccinated. These
results and their innovative combination can help in determining
policy, but should be considered in the relevant context, both in
terms of patterns of risk behaviour and opportunities for
vaccination. What coverage is possible in the different age groups
and who will deliver the vaccine and at what cost?
Our model generates numerical results and it is tempting to
regard the predictions as definite. However, there is great
uncertainty concerning both model structure and parameter
values. We have, for simplicity, only considered one HPV type
(HPV16), which is present in at least half of the cervical cancers.
There may be differences in the oncogenic potential of the different
hrHPV types, but with appropriate parameters the same model
could be used to explore other types. More significantly, we have
assumed complete naturally acquired immunity on clearance of
infection. The age of incidence of HPV infection and cervical
neoplasia suggest that a naturally derived type-specific immunity
occurs, and observational studies suggest that there is also cross
reactive natural immunity (Luostarinen et al, 1999, 2004), but their
impact and duration are uncertain. If we assumed no natural
immunity or a short duration of natural immunity, we would
expect the impact of vaccination to be greater and additional
coverage to add less. We would also expect to see higher rates of
incidence of HPV in older women, possibly increasing the value of
vaccinating at older ages. In contrast, we used reported sexual
behaviours (Haavio-Mannila et al, 2001) to describe the distribu-
tion of sexual activity, which limited the extremes of behaviour of
the model population. A greater variance in risk would reduce the
impact of a given vaccination coverage and make additional target
groups more attractive.
We assume the vaccine is 100% effective with lifelong duration
of protection. A lower vaccine efficacy would result in reduced
proportions of cases prevented but the difference between
vaccination strategies would not be affected. However, if duration
of protection is lower the proportion of cases prevented by
different strategies may be altered, particularly if the duration of
protection means that the vaccinated cohort would cease to be
protected by the time they reach the age of peak incidence. In
addition, the vaccine was assumed to have no effect on individuals
already infected with HPV. Although it has not yet been shown
conclusively that vaccines have any therapeutic effect, if they
significantly reduce infectiousness in those already infected,
vaccination at older ages would prevent more cases than we have
observed as a result of reductions in transmission. This is an
important consideration that needs further research.
So far the cost-effectiveness of HPV vaccination has not really
been considered in relation to implementing HPV into the national
vaccination programme (Goldie et al, 2004; Taira et al, 2004). The
logical extension of this analysis would be to attach costs to both
disease and vaccination. This would allow a cost-effectiveness
analysis including the incremental benefits associated with the
incremental costs of extending vaccination. Cost-effectiveness
analyses usually discount future health benefits at a rate per year,
which may nullify the observed advantage of vaccination at age 12
over age 15. The advantage of using a transmission-dynamic
model like ours in a cost-effectiveness analysis is that it allows
the investigation of the relative impact upon incidence of
vaccinating different groups, especially with respect to vaccinating
females vs both sexes. The current analysis allows qualitative
insights into how to focus vaccination campaigns, but more
detailed work is required to determine the feasibility and costs of
such campaigns.
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